Suradista NSC 651016 inhibits the angiogenic activity of CXCL12-stromal cell-derived factor 1alpha

CXCL12 (stromal cell-derived factor 1alpha), a ligand for CXCR4, has been shown to induce endothelial cell chemotaxis and to stimulate angiogenesis, suggesting that it may be a significant target for antiangiogenic therapy. Here we have tested suradista NSC 651016, a compound known to inhibit CXCL12...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2002-12, Vol.8 (12), p.3955
Main Authors: Schneider, Gregory P, Salcedo, Rosalba, Dong, Hui Fang, Kleinman, Hynda K, Oppenheim, Joost J, Howard, O M Zack
Format: Article
Language:English
Subjects:
Animals
Cell Movement - drug effects
Cells, Cultured - drug effects
Chemokine CXCL12
Chemokines, CXC - antagonists & inhibitors
Chemokines, CXC - toxicity
Chemotaxis - drug effects
Chickens
Endothelium, Vascular - drug effects
Endothelium, Vascular - metabolism
Humans
In Vitro Techniques
Monocytes - drug effects
Naphthalenesulfonates - pharmacology
Neovascularization, Pathologic - chemically induced
Neovascularization, Pathologic - prevention & control
Rats
Rats, Sprague-Dawley
Stromal Cells - drug effects
Stromal Cells - metabolism
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CXCL12 (stromal cell-derived factor 1alpha), a ligand for CXCR4, has been shown to induce endothelial cell chemotaxis and to stimulate angiogenesis, suggesting that it may be a significant target for antiangiogenic therapy. Here we have tested suradista NSC 651016, a compound known to inhibit CXCL12-induced monocyte chemotaxis, for its ability to inhibit CXCL12-induced angiogenic activity. NSC 651016 inhibited CXCL12-mediated endothelial cell chemotaxis in a dose-dependent manner. In addition, new vessel sprouting, by both rat and chick aorta in an angiogenesis model, was inhibited. Additionally, in vitro capillary-like structure formation induced by CXCL12 was inhibited by NSC 651016. Furthermore, NSC 651016 inhibited CXCL12-mediated angiogenesis in an in vivo s.c. assay. These data indicate that suradista NSC 651016 possesses in vitro and in vivo antiangiogenic activity and has the potential to interfere with neovacularization of tumors and their metastases.
ISSN:1078-0432